Guaifenesin Uses

sponsored
What is the dose of your medication?

What is Guaifenesin?

Geri-Guaifenesin Expectorant is used to reduce chest congestion caused by the common cold, flu, or chronic bronchitis.

Geri-Guaifenesin Expectorant helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.

There are many brands and forms of Guaifenesin available. Not all brands are listed on this leaflet.

Geri-Guaifenesin Expectorant may also be used for purposes not listed in this medication guide.

Guaifenesin indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Guaifenesin and hydrocodone is used to treat cough and reduce chest congestion caused by the common cold, flu, or allergies.

How should I use Guaifenesin?

Use Guaifenesin sustained-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Take Guaifenesin sustained-release tablets by mouth with or without food.
  • Drinking extra fluids while you are taking Guaifenesin sustained-release tablets is recommended. Check with your doctor for instructions.
  • Swallow Guaifenesin sustained-release tablets whole. Do not break, crush, or chew before swallowing.
  • If you miss a dose of Guaifenesin sustained-release tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Guaifenesin sustained-release tablets.

Uses of Guaifenesin in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

Guaifenesin is used to treat coughs and congestion caused by the common cold, bronchitis, and other breathing illnesses. This product is usually not used for ongoing cough from smoking or long-term breathing problems (such as chronic bronchitis, emphysema) unless directed by your doctor. Guaifenesin is an expectorant. It works by thinning and loosening mucus in the airways, clearing congestion, and making breathing easier.

If you are self-treating with this medication, it is important to read the package instructions carefully before you start using this product to be sure it is right for you.

Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. Therefore, do not use this product to treat cold symptoms in children younger than 6 years unless specifically directed by the doctor. Some products (such as long-acting tablets/capsules) are not recommended for use in children younger than 12 years. Ask your doctor or pharmacist for more details about using your product safely.

These products do not cure or shorten the length of the common cold. To decrease the risk for side effects, carefully follow all dosage directions. Do not give other cough-and-cold medication that might contain the same or similar ingredients. Ask the doctor or pharmacist about other ways to relieve cough and cold symptoms (such as drinking enough fluids, using a humidifier or saline nose drops/spray).

How to use 2/G

Take this medication by mouth with or without food, as directed by your doctor, usually every 4 hours. If you are self-treating, follow all directions on the product package. If you are uncertain about any of the information, ask your doctor or pharmacist.

Guaifenesin may have a bitter taste. Do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.

If you are using the liquid form of this medication, carefully measure the dose using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.

For powder packets, empty the entire contents of the packet onto the tongue and swallow. To prevent a bitter taste, do not chew.

Dosage is based on your age, medical condition, and response to treatment. Do not take more than 6 doses in a day. Do not increase your dose or take this drug more often than directed.

Drink plenty of fluids while taking this medication. Fluids will help to break up mucus and clear congestion.

Tell your doctor if your cough is accompanied by fever, severe sore throat, rash, persistent headache, or if it persists, returns, or worsens after 7 days. These may be signs of a serious medical problem. Seek immediate medical attention if you think you may have a serious medical problem.

Guaifenesin description

sponsored

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Guaifenesin is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)

Guaifenesin dosage

ORGANIDIN® NR (Guaifenesin)

Tablets — Adults and children 12 years of age and older: One to 2 tablets (200 mg to 400 mg) every four hours, not to exceed 2400 mg (12 tablets) in 24 hours.

PATIENTS SHOULD BE ADVISED TO KEEP THESE AND ALL DRUGS OUT OF THE REACH OF CHILDREN AND TO SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY IN CASE OF ACCIDENTAL OVERDOSE.

How supplied

ORGANIDIN® NR (Guaifenesin)

Tablets — Each round, scored, rose-colored tablet contains 200 mg Guaifenesin USP—available in bottles of 100 (NDC 0037-4312-01)

Storage

Store at controlled room temperature 20°-25°C (68°-77°F). Protect tablets from moisture. Keep bottle tightly closed.

To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-800-526-3840 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Meda Pharmaceuticals Inc. Somerset, New Jersey 08873-4120. Rev. 11/09

Guaifenesin interactions

See also:
What other drugs will affect Guaifenesin?

sponsored

In vitro results suggest that methadone undergoes hepatic N-demethylation by cytochrome P450 enzymes, principally CYP3A4, CYP2B6, CYP2C19 and to a lesser extent by CYP2C9 and CYP2D6. Coadministration of methadone with CYP inducers of these enzymes may result in a more rapid metabolism and potential for decreased effects of methadone, whereas administration with CYP inhibitors may reduce metabolism and potentiate methadones effects. Although antiretroviral drugs such as efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir+ritonavir combination are known to inhibit CYPs, they are shown to reduce the plasma levels of methadone, possibly due to their CYP induction activity. Therefore, drugs administered concomitantly with methadone should be evaluated for interaction potential; clinicians are advised to evaluate individual response to drug therapy.

Opioid Antagonists, Mixed Agonist/Antagonists, and Partial Agonists

As with other mu-agonists, patients maintained on methadone may experience withdrawal symptoms when given opioid antagonists, mixed agonist/antagonists, and partial agonists. Examples of such agents are naloxone, naltrexone, pentazocine, nalbuphine, butorphanol, and buprenorphine.

Anti-retroviral Agents

Abacavir, amprenavir, efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir+ritonavir combination - Coadministration of these anti-retroviral agents resulted in increased clearance or decreased plasma levels of methadone. Guaifenesin-maintained patients beginning treatment with these antiretroviral drugs should be monitored for evidence of withdrawal effects and methadone dose should be adjusted accordingly.

Didanosine and Stavudine - Experimental evidence demonstrated that methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Guaifenesin disposition was not substantially altered.

Zidovudine - Experimental evidence demonstrated that methadone increased the area under the concentration-time curve (AUC) of zidovudine which could result in toxic effects.

Cytochrome P450 Inducers

Guaifenesin-maintained patients beginning treatment with CYP3A4 inducers should be monitored for evidence of withdrawal effects and methadone dose should be adjusted accordingly. The following drug interactions were reported following coadministration of methadone with inducers of cytochrome P450 enzymes:

Rifampin - In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.

Phenytoin - In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.

St. Johns Wort, Phenobarbital, Carbamazepin/strong>Administration of methadone along with other CYP3A4 inducers may result in withdrawal symptoms.

Cytochrome P450 Inhibitors

Since the metabolism of methadone is mediated primarily by CYP3A4 isozyme, coadministration of drugs that inhibit CYP3A4 activity may cause decreased clearance of methadone. The expected clinical results would be increased or prolonged opioid effects. Thus, methadone-treated patients coadministered strong inhibitors of CYP3A4, such as azole antifungal agents (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), with methadone should be carefully monitored and dosage adjustment should be undertaken if warranted. Some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine) may increase methadone plasma levels upon coadministration with methadone and result in increased opiate effects and/or toxicity.

Voriconazole - Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the Cmax and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg QD). The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed.

Others

Monoamine Oxidase (MAO) Inhibitors - Therapeutic doses of meperidine have precipitated severe reactions in patients concurrently receiving monoamine oxidase inhibitors or those who have received such agents within 14 days. Similar reactions thus far have not been reported with methadone. However, if the use of methadone is necessary in such patients, a sensitivity test should be performed in which repeated small, incremental doses of methadone are administered over the course of several hours while the patients condition and vital signs are under careful observation.

Desipramine - Blood levels of desipramine have increased with concurrent methadone administration.

Potentially Arrhythmogenic Agents

Extreme caution is necessary when any drug known to have the potential to prolong the QT interval is prescribed in conjunction with methadone. Pharmacodynamic interactions may occur with concomitant use of methadone and potentially arrhythmogenic agents such as class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers.

Caution should also be exercised when prescribing methadone concomitantly with drugs capable of inducing electrolyte disturbances (hypomagnesemia, hypokalemia) that may prolong the QT interval. These drugs include diuretics, laxatives, and, in rare cases, mineralocorticoid hormones.

Interactions with Alcohol and Drugs of Abuse

Guaifenesin may be expected to have additive effects when used in conjunction with alcohol, other opioids or CNS depressants, or with illicit drugs that cause central nervous system depression. Deaths have been reported when methadone has been abused in conjunction with benzodiazepines.

Anxiety - Since methadone as used by tolerant patients at a constant maintenance dosage does not act as a tranquilizer, patients who are maintained on this drug will react to life problems and stresses with the same symptoms of anxiety as do other individuals. The physician should not confuse such symptoms with those of narcotic abstinence and should not attempt to treat anxiety by increasing the dose of methadone. The action of methadone in maintenance treatment is limited to the control of narcotic withdrawal symptoms and is ineffective for relief of general anxiety.

Acute Pain - Maintenance patients on a stable dose of methadone who experience physical trauma, postoperative pain or other acute pain cannot be expected to derive analgesia from their existing dose of methadone. Such patients should be administered analgesics, including opioids, in doses that would otherwise be indicated for non-methadone-treated patients with similar painful conditions. Due to the opioid tolerance induced by methadone, when opioids are required for management of acute pain in methadone patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients.

Risk of Relapse in Patients on Guaifenesin Maintenance Treatment of Opioid Addiction

Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms. Presentation of these symptoms have been associated with an increased risk of susceptible patients to relapse to illicit drug use and should be considered when assessing the risks and benefit of methadone use.

Tolerance and Physical Dependence

Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and/or tolerance are not unusual during chronic opioid therapy.

If methadone is abruptly discontinued in a physically dependent patient, an abstinence syndrome may occur. The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

In general, chronically administered methadone should not be abruptly discontinued.

Special-Risk Patients

Guaifenesin should be given with caution and the initial dose reduced in certain patients, such as the elderly and debilitated and those with severe impairment of hepatic or renal function, hypothyroidism, Addisons disease, prostatic hypertrophy, or urethral stricture. The usual precautions appropriate to the use of parenteral opioids should be observed and the possibility of respiratory depression should always be kept in mind.

Guaifenesin side effects

See also:
What are the possible side effects of Guaifenesin?

sponsored

Applies to Guaifenesin: oral capsule, oral capsule extended release, oral elixir, oral liquid, oral packet, oral solution, oral syrup, oral tablet, oral tablet extended release

In addition to its needed effects, some unwanted effects may be caused by Guaifenesin (the active ingredient contained in Guaifenesin LA). In the event that any of these side effects do occur, they may require medical attention.

Minor Side Effects

Some of the side effects that can occur with Guaifenesin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common or rare:

  • Diarrhea
  • dizziness
  • headache
  • hives
  • nausea or vomiting
  • skin rash
  • stomach pain

Guaifenesin contraindications

See also:
What is the most important information I should know about Guaifenesin?

Guaifenesin is contraindicated in patients with a known hypersensitivity to methadone hydrochloride or any other ingredient in DOLOPHINE.

Guaifenesin is contraindicated in any situation where opioids are contraindicated such as: patients with respiratory depression (in the absence of resuscitative equipment or in unmonitored settings), and in patients with acute bronchial asthma or hypercarbia.

Guaifenesin is contraindicated in any patient who has or is suspected of having a paralytic ileus.

Active ingredient matches for Guaifenesin:

Guaifenesin


Unit description / dosage (Manufacturer)Price, USD
Diabetic Tussin Max St 10-200 mg/5ml Liquid 118ml Bottle$ 15.99
Naldecon Senior EX 200 mg/5ml Syrup 118ml Bottle$ 15.99
P-ephed w/guaifen tablet$ 1.21
P-ephedrine-guaifen la tablet$ 1.14
Guaifen/p-ephed tablet sa$ 1.01
Organidin nr 200 mg tablet$ 0.89
Mucinex dm er 1200-60 mg tablet$ 0.80
Pseudoephedrine-guaifen tr tablet$ 0.76
Humibid e 400 mg tablet$ 0.74
Mucinex d er tablet$ 0.73
P-ephed w/guaifen tablet sr$ 0.67
Pseudoephedrine-guaif sr tablet$ 0.63
Guaifenesin/p-ephedrine tablet$ 0.62
P-ephed-guaifen tablet la$ 0.60
Kid's mucinex mini-melts pack$ 0.57
Mucinex cough mini-melt pack$ 0.57
Mucinex d tablet$ 0.54
Organidin NR 100 mg/5ml Liquid$ 0.49
Codeine 10 mg-guai 300 mg liq$ 0.46
Mucinex er 600 mg tablet$ 0.44
Mucinex 600 mg tablet$ 0.42
Mucinex full force nasal spray$ 0.42
Mucinex moisture smart nas spr$ 0.42
Tussi-Organidin NR 300-10 mg/5ml Liquid$ 0.39
Mucus relief 400 mg tablet$ 0.37
Codeine-guaifen 10 mg-200 mg liq$ 0.28
Guaifenesin 200 mg tablet$ 0.28
Guaifenesin-dm 400-20 mg tablet$ 0.25
Robitussin coughgels$ 0.25
Diabetic tussin ex 400 tablet$ 0.20
G-fenesin dm 20-400 mg caplet$ 0.20
Organ-i nr 200 mg tablet$ 0.20
G-fenesin 400 mg caplet$ 0.19
Guaifenesin 400 mg tablet$ 0.16
Chest congestion relief tablet$ 0.15
Guaifen p-ephed caplet er$ 0.15
Fenesin dm ir tablet$ 0.13
Fenesin pe ir tablet$ 0.13
Guaifenesin nr liquid$ 0.13
Fenesin ir 400 mg tablet$ 0.10
Guaifenesin-dm nr liquid$ 0.10
Guaifenesin-DM 100-10 mg/5ml Liquid$ 0.09
Robitussin dm to go liquid$ 0.09
Guaiacol liquid purified$ 0.08
Guaifenesin dac oral solution$ 0.08
Guaifenesin nr 100 mg/5 ml$ 0.08
Children's mucinex cough liq$ 0.06
Mucinex cold liquid$ 0.06
Naldecon-dx senior$ 0.06
Child's mucinex 100 mg/5 ml lq$ 0.05
Guiatuss-dm syrup$ 0.05
Adlt robitussin cough-cold-flu$ 0.04
Adt robitussin cough-cold d lq$ 0.04
Adult robitussin cough syrup$ 0.04
Guiatuss DAC 30-10-100 mg/5ml Solution$ 0.04
Robitussin chest congest syrup$ 0.04
Robitussin cough & cold liquid$ 0.04
Robitussin cough-cold liquid$ 0.04
Robitussin cough-cong syrup$ 0.04
Robitussin dm max liquid$ 0.04
Robitussin long-acting liq$ 0.04
Robitussin pe head & chest liq$ 0.04
Robitussin-cough-chest-cong lq$ 0.04
Robitussin-dm cough syrup$ 0.04
Scot-tussin 100 mg/5 ml liq$ 0.04
Guiatuss ac syrup$ 0.03
Guiatuss-dac syrup$ 0.03
Sb cough control syrup$ 0.03
Guaifenesin ac cough syrup$ 0.02
Guaifenesin dm syrup$ 0.02
Guiatuss dm syrup$ 0.02
Guiatuss-pe syrup$ 0.02
Guaifenesin / S.C. 200 mg x 1000's
Guaifenesin solution 100 mg/5mL (Pharmaceutical Associates, Inc. (US))
Guaifenesin liquid 300 mg/15mL (Cardinal Health (US))
Guaifenesin tablet 200 mg/1 (Major Pharmaceuticals (US))
Guaifenesin liquid 100 mg/5mL (Cardinal Health (US))
Guaifenesin tablet 400 mg/1 (CARDINAL HEALTH, INC. (US))
Guaifenesin liquid 200 mg/10mL (Cardinal Health (US))
Kid's mucinex mini-melts pack$ 0.57
Children's mucinex cough liq$ 0.06
Child's mucinex 100 mg/5 ml lq$ 0.05
Robitussin cough & cold liquid$ 0.04
Robitussin pe head & chest liq$ 0.04

List of Guaifenesin substitutes (brand and generic names):

Syrup; Oral; Guaifenesin 200 mg / 5 ml
Liquid; Oral; Guaifenesin 100 mg / 5 ml
Liquid; Oral; Guaifenesin 100 mg / 5 ml
Guaphen 600 mg
Guaphen 20 mg/1 mL x 1 mL
Guaphen 20 mg/1 mL x 120 mL
Guaphen 20 mg/1 mL x 200 mL

References

  1. DailyMed. "GUAIFENESIN; HYDROCODONE BITARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "guaifenesin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "Guaifenesin". http://www.drugbank.ca/drugs/DB00874 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Guaifenesin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Guaifenesin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


4 consumers reported age

Users%
< 11
25.0%
30-451
25.0%
1-51
25.0%
16-291
25.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 14 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 ndrugs.com All Rights Reserved